Skip to main content

Table 4 Adverse events ≥grade 3 in the mFOLFOX6 arm (n=50)

From: Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)

 

All grades

Grade 3–4

n (%)

n (%)

Laboratory findings

 Neutropenia

39 (78.0)

16 (32.0)

 Leukopenia

28 (56.0)

3 (6.0)

 Anemia

41 (82.0)

2 (4.0)

 Hypoalbuminemia

44 (88.0)

2 (4.0)

 Hyponatremia

18 (36.0)

2 (4.0)

 Increased AST

38 (76.0)

1 (2.0)

 Hypokalemia

14 (28.0)

1 (2.0)

 Hyperkalemia

12 (24.0)

1 (2.0)

Clinical findings

 Anorexia

25 (50.0)

2 (4.0)

Catheter related

 Infection

2 (4.0)

2 (4.0)

 Fatigue/malaise

23 (46.0)

1 (2.0)

 Nausea

21 (42.0)

1 (2.0)

 Diarrhea

21 (42.0)

1 (2.0)

 Vascular disorder

1 (2.0)

1 (2.0)

 Hyperglycemia

1 (2.0)

1 (2.0)

  1. AST: aspartate aminotransferase, mFOLFOX6: folinic acid, 5-FU, and oxaliplatin